{"id":2908,"date":"2026-08-20T10:07:45","date_gmt":"2026-08-20T10:07:45","guid":{"rendered":"https:\/\/valutednews.com\/?p=2908"},"modified":"2026-08-20T10:07:45","modified_gmt":"2026-08-20T10:07:45","slug":"huidagene-merck-moderna-vaccine-fda-readout-newsletter","status":"publish","type":"post","link":"https:\/\/valutednews.com\/?p=2908","title":{"rendered":"Huidagene, Merck Moderna vaccine, FDA: Readout Newsletter"},"content":{"rendered":"
<\/div>

<\/p>\n

\n

Elaine\u2019s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter<\/a>, and co-hosts STAT\u2019s weekly biotech podcast, The Readout Loud<\/a>. You can reach Elaine on Signal at elaineywchen.70.<\/p>\n<\/div>\n

\n

Want to stay on top of the science and politics driving biotech today?\u00a0Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/em><\/p>\n

Good morning. We\u2019re sending the newsletter a bit early today since we\u2019ve got some breaking news for you \u2014 plus a new FDA commissioner nominee.<\/p>\n

Merck and\u00a0Moderna\u2019s mRNA cancer vaccine succeeds in late-stage trial<\/h2>\n

Scientists have long hoped that personalized mRNA cancer vaccines could be the next big breakthrough in oncology treatment. Today, Merck and Moderna said they had shown in a randomized late-stage trial for the first time that such a drug can work.<\/p>\n

\n
\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n<\/p><\/div>\n

\t\t\t\"STAT+\"\/<\/p>\n

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a>
\n\t\t\t\t<\/span><\/p>\n

This article is exclusive to STAT+ subscribers<\/h2>\n

Unlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/h3>\n

Already have an account? Log in<\/a><\/p>\n

\n
\n\t\t\t\t\t\t